- Raw materials
- Antibacterials
- Gusperimus
Gusperimus API Manufacturers & Suppliers
0 verified results
All Gusperimus data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Gusperimus | CAS No: 98629-43-7 | GMP-certified suppliers
A medication that selectively modulates immune responses, investigated for autoimmune diseases like lupus nephritis and granulomatosis with polyangiitis with immunosuppressive and antineoplastic properties.
Therapeutic categories
Product Snapshot
- Gusperimus is an injectable small molecule formulation
- It is primarily investigated for immunomodulatory therapeutic applications
- The compound is currently in the investigational stage and has not received FDA or EMA approval
Clinical Overview
Gusperimus has been investigated primarily in clinical trials targeting autoimmune conditions such as lupus nephritis and Wegener’s granulomatosis (now more commonly referred to as granulomatosis with polyangiitis). These investigational contexts reflect its role in modulating immune responses, although a formally approved therapeutic indication for gusperimus has not been established.
Within pharmacological classification, gusperimus is recognized as an immunosuppressive and antineoplastic agent with selective immunomodulatory properties. It falls under several drug categories including amidines, antibiotics, and protective agents with noted radiation-protective potential. Despite its categorization, detailed pharmacodynamics and specific mechanisms of action remain incompletely characterized in the literature, limiting a comprehensive mechanistic description.
Key ADME parameters such as absorption, distribution, metabolism, and excretion for gusperimus have not been extensively documented in public sources, reflecting its investigative status. Similarly, safety and toxicity profiles are mainly derived from early-phase clinical data and preclinical studies, with no wide-ranging or regulatory-approved safety data publicly available.
Notable usage contexts for gusperimus remain confined to clinical research and experimental therapeutic applications rather than standard clinical practice. There are no widely recognized commercial brands associated with this API, reinforcing its current status as an investigational compound.
From an API procurement and quality perspective, sourcing gusperimus requires careful consideration of purity standards, stability profiles, and regulatory compliance applicable to investigational immunosuppressive agents. Suppliers should provide comprehensive documentation including certificate of analysis, impurity profiles, and batch-to-batch consistency to meet the stringent demands of clinical research and formulation development.
Identification & chemistry
| Generic name | Gusperimus |
|---|---|
| Molecule type | Small molecule |
| CAS | 98629-43-7 |
| UNII | UJ0ZJ76DO9 |
| DrugBank ID | DB12692 |
Formulation & handling
- Gusperimus is a small molecule with low lipophilicity and limited water solubility, indicating potential formulation challenges for oral delivery. The compound's chemical class suggests stability considerations related to the acylated amino acid moiety under physiological conditions. As an investigational agent, handling protocols should account for its stability profile and solubility limitations during formulation development.
Regulatory status
Gusperimus is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
